Shionogi & Co. Ltd. won a $375 million project agreement from the Rapid Response Partnership Vehicle to develop its 3CL protease inhibitor, S-892216, as a long-acting injectable for COVID-19 ...

This programme is designed to advance next-generation vaccines, therapeutics, and other tools to combat Covid-19. The therapeutic, dubbed S-892216, leverages protease inhibitor technology to block the ...

This prospective case-control study included 85 patients with lung involvement related to the COVID-19 virus and a group of ...

Their new discovery is detailed in the paper, "Design of novel and highly selective SARS-CoV-2 main protease inhibitors ...

Investigators at The Scripps Research Institute and Rensselaer Polytechnic Institute have designed novel covalent inhibitors of SARS-CoV-2 papain-like protease (PLpro) and assessed their drug ...

Announcing a new article publication for BIO Integration journal. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first identified in China in December 2019, rapidly spread worldwide, ...

a protease inhibitor used to treat reflux esophagitis and chronic pancreatitis. The organization is also raising funds to support COVID-related trials of remdesivir, a broad-spectrum antiviral ...

a 3CL protease inhibitor, as a long-acting injectable for COVID-19 pre-exposure prophylaxis. RRPV is a consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part ...